cdmo.directory
← Compare landing

Boston Institute of Biotechnology, LLC vs Lonza Cell & Gene Technologies

Auto-generated comparison by BioBM Editorial AI. This page highlights available profile evidence side by side and avoids drawing conclusions from missing fields.

Markdown mirror: /api/markdown/compare/bostonbib/lonza

CategoryBoston Institute of Biotechnology, LLCLonza Cell & Gene Technologies
Listed sitecdmocdmo
SummaryFull-service CDMO offering cGMP and non-GMP mammalian, microbial, gene therapy, and cell therapy manufacturing from cell line development through commercial-scale fill/finish.Lonza is the world's leading CDMO, founded in Switzerland in 1897, serving the healthcare industry with integrated offerings for contract development and manufacturing of therapies across multiple modalities.
Services
  • Analytical Method Development & Validation
  • ICH Stability Studies
  • Cell-Line Development
  • Protein Engineering
  • Analytical Method Development & Validation
  • Process Development
  • Formulation Development
  • Technology Transfer
  • Recombinant Protein Manufacturing
  • Monoclonal Antibody (mAb) Manufacturing
  • Biologics Development & Manufacturing
  • API Synthesis & Manufacturing
  • Small Molecule Development & Manufacturing
  • Regulatory Affairs
  • Cell Therapy Manufacturing
  • Upstream Processing
  • Downstream Processing
  • Quality Control Testing
  • Microbiology Services
  • Translational Research
  • CMC Analytical Development
  • Stability Testing & Storage
Modalities
  • Biologics (Monoclonal Antibodies)
  • Biologics (Other)
  • Gene Therapy
  • Cell Therapy
  • Peptide
  • Biologics (Monoclonal Antibodies)
  • Biologics (Other)
  • Cell Therapy
  • Gene Therapy
IndicationsData not yet provided.Data not yet provided.
Locations
  • Headquarters, Southborough, Massachusetts, United States
  • Headquarters, Basel, Basel-Stadt, Switzerland
CertificationsData not yet provided.Data not yet provided.
ReviewsReview summary appears after site-level review signal gate opens.Review summary appears after site-level review signal gate opens.